Oneness Biotech

Taiwan’s Oneness Biotech (TPEx.4743) and its partner Microbio (Shanghai) have secured a lucrative licensing deal with China mainland firm CR Double-Crane. The agreement grants CR Double-Crane a 20-year exclusive license to commercialize Fespixon (ON101), a novel etiology-driven solution designed to regulate macrophages and enhance tissue repair, within the Chinese market.…